Calmangafodipir

Drug Profile

Calmangafodipir

Alternative Names: PledOx; PP-095

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator PledPharma
  • Class Acetates; Chemoprotectants; Ethylenediamines; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chemotherapy-induced damage

Most Recent Events

  • 09 Mar 2017 Phase-IIb development is ongoing in Germany, Georgia and Serbia
  • 20 Oct 2016 PledPharma announces intention to submit NDA and MAA to the US FDA and EMA
  • 20 Oct 2016 PledPharma plans two phase III trials for Colorectal cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top